Supernus, Inc. (SUPN) stock
SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$28.96−0.08 (-0.28%)
Close on Nov 18, 2026Market cap $3.42BP/E 8.1Yield –
Supernus revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Supernus's revenue for the twelve months ending Sep 30, 2026 was $1.37B, up 16.3% year over year. For fiscal 2025 it was $1.24B, up 4.3% from the year before. The highest annual figure on record is $1.24B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | +4.3% |
| FY2024 | Dec 31, 2024 | $1.19B | +8.7% |
| FY2023 | Dec 31, 2023 | $1.09B | +21.3% |
| FY2022 | Dec 31, 2022 | $901.00M | +13.9% |
| FY2021 | Dec 31, 2021 | $791.00M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $356.00M | +13.4% |
| Q2 FY2026 | Jun 30, 2026 | $343.00M | +13.6% |
| Q1 FY2026 | Mar 31, 2026 | $317.00M | +19.2% |
| Q4 FY2025 | Dec 31, 2025 | $358.00M | +19.7% |
| Q3 FY2025 | Sep 30, 2025 | $314.00M | +2.3% |
| Q2 FY2025 | Jun 30, 2025 | $302.00M | +1.0% |
| Q1 FY2025 | Mar 31, 2025 | $266.00M | -6.3% |
| Q4 FY2024 | Dec 31, 2024 | $299.00M | – |
| Q3 FY2024 | Sep 30, 2024 | $307.00M | – |
| Q2 FY2024 | Jun 30, 2024 | $299.00M | – |
| Q1 FY2024 | Mar 31, 2024 | $284.00M | – |
See a number that looks wrong?